Stada Reports 22% Revenue Growth in First Quarter

Stada, a prominent player in the pharmaceutical industry, has announced a significant increase in its revenue for the first quarter of 2025. The company reported a total revenue of EUR1.081 billion, reflecting a growth of 4% compared to the same period last year. This growth has been notably bolstered by the performance of its specialty pharmaceuticals, particularly the biosimilar Uzpruvo (Ustekinumab), which was introduced in Europe in July 2024. According to the company, this product contributed to a remarkable 22% growth in its specialty segment.

In addition to Uzpruvo, the continued success of existing biosimilars and the launch of new products such as Bosutinib, Nilotinib, and Paliperidone have further reinforced the company's revenue growth.

Stada's revenue from generics showed modest growth, with a 1% increase in the domestic market compared to a particularly strong quarter last year. However, international sales of generics saw a substantial rise, achieving growth in the high single digits. This increase was attributed to the recent market introductions of medications like Dabigatran and Rivaroxaban.

Despite facing challenges in the Consumer Healthcare division, which experienced a slight decline of 1% due to a weak cough and cold season and inventory reductions among market participants, Stada's overall outlook remains optimistic. The CEO expressed confidence in the company's ability to maintain its growth trajectory throughout 2025, citing minimal dependence on the U.S. market and resilience against tariffs and currency fluctuations.

Furthermore, Stada's recently published sustainability report highlights the company's commitment to sustainable practices. The report, evaluated by Sustainalytics, placed Stada among the top 3% of pharmaceutical companies regarding environmental, social, and governance (ESG) standards.

With a legacy of 125 years as a partner in the pharmacy sector in Germany, Stada continues to expand its footprint globally, offering a diverse portfolio of generics, specialty pharmaceuticals, and over-the-counter healthcare products in more than 100 countries.